WilmerHale Advises Coherus Oncology on its Clinical Supply Agreement with Johnson & Johnson to Evaluate Tagmokitug in Combination with Pasritamig

WilmerHale Advises Coherus Oncology on its Clinical Supply Agreement with Johnson & Johnson to Evaluate Tagmokitug in Combination with Pasritamig

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.

Coherus Oncology, Inc. (NASDAQ: CHRS) entered into a clinical supply agreement with Johnson & Johnson to evaluate tagmokitug (CHS-114), Coherus Oncology’s investigational anti-CCR8 cytolytic monoclonal antibody, in combination with pasritamig, a T-cell engaging bispecific antibody, in a Phase 1b clinical study in patients with metastatic castration-resistant prostate cancer (mCRPC). 

WilmerHale advised Coherus Oncology in connection with the agreement.

Under the terms of the clinical supply agreement, Johnson & Johnson will provide pasritamig to Coherus, which will be the sponsor of the Phase 1b clinical trial. Johnson & Johnson and Coherus each retain all commercial rights to their respective compounds, including as monotherapy or as combination treatments.

The WilmerHale team was led by Jekkie Kim and included Mizuna Sekine.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel